Sanofi Halts Multaq Trial Early Due To Cardiac Events
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi is facing another safety issue with its antiarrhythmic drug Multaq (dronedarone) with the termination of a Phase IIIb clinical trial in patients with permanent atrial fibrillation due to an increase in cardiovascular events.